Advanced Hormone Care: A Comprehensive Guide

Integrative Hormone Health, Iron Metabolism, and Safer Care Pathways: An Educational Post by Dr. Alexander Jimenez, DC, APRN, FNP-BC, CFMP, IFMCP, ATN, CCST

Abstract

In this educational post, I guide you through a practical, research-informed journey across several intertwined topics I encounter in clinic every week: optimizing iron status and understanding ferritin; selecting intrauterine devices (IUDs) and navigating progestin families; the nuanced use of progesterone (oral and sublingual) and how dosing changes physiology; evaluating cortisol and thyroid markers with the right tests at the right time; supporting men’s reproductive health when testosterone therapy is used or discontinued; individualizing hormone therapy in patients with a history of breast pathology; addressing post–transient ischemic attack (TIA) and neurologic concerns around hormones; aligning estriol and estradiol choices to receptor biology; and troubleshooting thyroid symptoms when labs and lived experience don’t align. Throughout, I integrate chiropractic-informed, whole-person care to improve outcomes—leveraging biomechanics, autonomic balance, sleep, exercise, nutrition, and gut health—while presenting current evidence from leading researchers using modern, evidence-based methods. I include clinical observations from my practice (Sciatica Clinic) and professional notes from my LinkedIn case discussions, with an emphasis on practical workflows you can apply now.

Key takeaways:

• Iron matters, but context matters more: absorption, hemorrhage, and inflammation reshape ferritin and transferrin saturation.
• Not all progestins are the same: families differ in clot risk and neuropsychologic effects; route and dose reshape tolerance.
• Use the right test for the right question: salivary multi-point cortisol and comprehensive thyroid panels prevent missteps.
• Individualized hormone care can be safe and effective—even after complex oncologic histories—when co-managed and risk-stratified.
• Integrative chiropractic care complements endocrine therapies by optimizing neuromusculoskeletal function, vagal tone, and metabolic flexibility.

Iron Metabolism, Ferritin, and Why “Low Iron” Is Never One Thing

When I evaluate fatigue, dizziness, hair shedding, or exercise intolerance, I start with a comprehensive iron panel, not just a single number. Ferritin is a useful but imperfect biomarker. It is both an iron-storage protein and an acute-phase reactant that rises during systemic inflammation.

• Key labs I order:
  • Serum ferritin
  • Serum iron
  • Total iron-binding capacity (TIBC)
  • Transferrin saturation
  • Complete blood count (CBC) with indices
  • C-reactive protein (CRP) or hs-CRP

Physiology in brief:

• Ferritin mirrors iron stores, but inflammation can elevate ferritin independent of true iron sufficiency. A low ferritin (<30 ng/mL) typically indicates depleted stores; however, a “normal” ferritin with high CRP may mask functional iron deficiency as iron is sequestered by hepcidin during inflammation (Ganz & Nemeth, 2012).
• Transferrin saturation <20% with low ferritin supports iron deficiency; low saturation with high ferritin suggests anemia of chronic inflammation.

Why do patients become iron-deficient?

• Blood loss: GI sources (occult bleeding, gastritis, IBD), heavy menses, postpartum loss.
• Impaired absorption: celiac disease, H. pylori, achlorhydria, bariatric surgery, high calcium or phytates at meals.
• Increased demand: pregnancy, endurance training.
• Rare pediatric/neonatal considerations: transient newborn physiologic shifts and blood sampling can influence early labs.

Clinical reasoning:

• Before iron repletion, I identify the “why.” Iron infusion or aggressive oral repletion, without identifying hemorrhage or malabsorption, is a short-term fix.
• I often pair iron with vitamin C and separate it from calcium to improve absorption; I assess for hepcidin-mediated inhibition when inflammation is high and address the inflammatory driver first (Camaschella, 2015).

Integrative chiropractic fit:

• Inflammatory tone is influenced by sleep, autonomic balance, and movement. I use gentle spinal manipulative therapy, breathing drills, and cervical/diaphragmatic mechanics to improve vagal tone, enhance gut motility, and reduce inflammation, which can normalize hepcidin rhythms and improve iron utilization.

Selected evidence:

• Hepcidin regulation and the anemia of inflammation (Ganz & Nemeth, 2012).
• Iron deficiency pathophysiology and management (Camaschella, 2015).

References:

• Hepcidin in iron metabolism and anemia of inflammation (Ganz & Nemeth, 2012)
• Iron-deficiency anemia (Camaschella, 2015)

Choosing IUDs and Understanding Progestin Families

Not all progestins are created equal. Their androgenic, estrogenic, and thrombotic profiles differ by family.

• Common categories and notes:
  • Levonorgestrel (LNG, e.g., Mirena): potent local progestin effect with low systemic levels; may lower bleeding and dysmenorrhea; thrombotic risk appears lower than systemic progestins (Dragoman et al., 2018).
  • Norethindrone and derivatives: different androgenicity; oral forms can affect lipids and mood variably.
  • Progesterone (bioidentical micronized): distinct from synthetic progestins; oral micronized progesterone shows a neutral or lower VTE risk compared to some synthetic progestins (Canonico et al., 2007).

Why the levonorgestrel IUD works:

• Primarily a local endometrial effect—thickens cervical mucus, thins endometrium, and blunts prostaglandin signaling—reducing bleeding and cramps. Localization limits hepatic first-pass effects and minimizes systemic coagulation changes (Nelson, 2021).

Clinical reasoning for selection:

• In patients with migraine with aura or thrombotic risk concerns, I favor LNG-IUD for contraception and menorrhagia control due to its local action.
• For estrogen therapy when a uterus is present, local or systemic progestin is needed to protect the endometrium; LNG-IUD can provide endometrial protection while minimizing systemic exposure.

Integrative chiropractic fit:

• Pelvic floor dysfunction often coexists with dysmenorrhea or heavy bleeding. My team integrates pelvic floor therapy and lumbopelvic stabilization to reduce nociceptive input and sympathetic overdrive, supporting better tolerance of IUD placement and reduced pelvic pain.

References:

• Levonorgestrel intrauterine system: mechanisms and use (Nelson, 2021)
• Hormone therapy and VTE risk by progestogen type (Canonico et al., 2007)
• Contraceptive choice and thrombotic risk (Dragoman et al., 2018)

Progesterone Dosing, Tolerance, and Why Route Matters

I routinely see patients who “don’t tolerate progesterone.” Most tolerate it when we match dose, timing, and route to physiology.

• Oral micronized progesterone:
  • First-pass hepatic metabolism generates neuroactive metabolites (e.g., allopregnanolone) that can cause sedation or paradoxical dysphoria in sensitive patients (Schiller et al., 2014).
  • 100 mg at bedtime is well tolerated by most; if grogginess occurs, I adjust the dose or timing.
• Sublingual troches:
  • Avoid first-pass metabolism; bioavailability roughly doubles compared with the oral route. Clinically, 100 mg sublingual is approximately equivalent to 200 mg oral for systemic effects.
  • Flexible dosing (e.g., quarter troches) allows fine-tuning for sleep or mood.

Why I choose sublingual for sensitive patients:

• Faster onset for sleep; lower neurosteroid spikes; fewer “hangover” effects.
• For severe PMS/PMDD, luteal-phase pulsing with sublingual progesterone can stabilize GABAergic tone.

Safety rationale:

• Bioidentical progesterone has a favorable cardiovascular and breast cancer risk profile compared with some synthetic progestins, according to observational data (Fournier et al., 2008). Individualization remains key.

Integrative chiropractic fit:

• I layer in circadian routines (morning light, consistent sleep windows), cervical/thoracic mobilizations to ease breathing, and slow exhalation drills to potentiate the GABAergic calming effect of progesterone.

References:

• Progesterone and neurosteroids: mood/sleep (Schiller et al., 2014)
• HRT and breast cancer by progestogen type (Fournier et al., 2008)

Cortisol Testing and When a Single AM Level Isn’t Enough

If I need to understand diurnal HPA-axis behavior, I use a 4–5-point salivary or dried-spot cortisol test throughout the day. A single AM cortisol can rule out frank adrenal insufficiency, but misses the curve shape.

• Physiologic basis:
  • The cortisol awakening response and diurnal slope predict metabolic risk and sleep quality; a flattened diurnal slope is linked to inflammation and fatigue (Adam et al., 2017).
• Practical approach:
  • For suspected HPA-axis dysregulation, I order multi-point testing.
  • For acute screening, I add an 8 AM serum cortisol to labs like fasting glucose/insulin when assessing metabolic stress.

Integrative chiropractic fit:

• I introduce graded exercise, postural decompression, and breathing to modulate autonomic tone; we also address sleep timing and light exposure to restore a healthy diurnal cortisol rhythm.

References:

• Diurnal cortisol and health (Adam et al., 2017)

Male Fertility, Testosterone Therapy, and Short-Term Clomiphene

When young men or those considering testosterone want to preserve fertility, we avoid long-term estrogen receptor blockade but may use short courses of clomiphene citrate.

• Physiology:

  • Exogenous testosterone suppresses GnRH, lowering LH/FSH and reducing intratesticular testosterone and spermatogenesis.
  • Clomiphene blocks hypothalamic estrogen receptors, raising LH/FSH to stimulate endogenous testosterone and sperm production (Patel et al., 2019).

Clinical reasoning:

• In men in their 20s–30s seeking conception within 6–12 months, I consider 3–6 months of clomiphene to increase sperm count and testosterone, then reassess.
• After stopping androgens/peptides, a brief course of SERMs may hasten spermatogenic recovery.

Lifestyle first:

• Diet quality, resistance training, sleep, weight reduction, and gut health can substantially improve testosterone and fertility without pharmaceuticals. I’ve seen total testosterone rise from ~300 ng/dL to 700–800 ng/dL over 6–9 months with dedicated lifestyle changes.

Integrative chiropractic fit:

• Correcting thoracic mobility and rib cage mechanics improves contributors to sleep-disordered breathing; lumbar-pelvic stability supports training adherence; we also program progressive resistance exercise with recovery metrics.

References:

• Clomiphene for male hypogonadism/fertility (Patel et al., 2019)

Breast Pathology, Receptors, and Individualized Hormone Decisions

Terminology matters for decision-making and informed consent. Ductal carcinoma in situ (DCIS) is non-invasive and considered stage 0; it is a precursor lesion managed actively but biologically distinct from invasive carcinoma (Wapnir & Dignam, 2019). Receptor positivity alone is not a contraindication to all hormones; risk is contextual.

Clinical approach I use:

• Shared decision-making with oncology, documenting risks and benefits, and considering:
  • Time since diagnosis and treatment completion.
  • Extent of surgery (e.g., bilateral mastectomy vs. lumpectomy).
  • Current endocrine therapy (e.g., tamoxifen, aromatase inhibitors).
  • Symptom burden (vasomotor, bone, cognition, cardiometabolic).

Evidence overview:

• For women with prior breast cancer, systemic menopausal hormone therapy is generally not recommended by guidelines due to recurrence risk uncertainty; however, low-dose vaginal estrogen for severe genitourinary symptoms may be considered in selected cases with oncology input (North American Menopause Society [NAMS], 2023).
• After bilateral mastectomy, systemic risk calculus changes, but decisions remain individualized.

Integrative chiropractic fit:

• We address bone density with resistance training programs, impact loading when appropriate, balance training, and spinal mechanics; autonomic regulation helps vasomotor stability. These non-pharmacologic supports often reduce the dose or need for systemic hormones.

References:

• DCIS outcomes and management (Wapnir & Dignam, 2019)
• NAMS 2023 position statement on hormone therapy (NAMS, 2023)

Post-TIA, Migraine, and Hormones: Rethinking Old Assumptions

Old teaching linked “estrogen” broadly to stroke and migraine risk. Modern nuance:

• Oral ethinyl estradiol at higher doses elevates stroke risk, especially in smokers or migraine with aura (Sacco et al., 2017).
• Transdermal estradiol at low doses appears to have a more favorable thrombotic profile than oral routes in menopausal therapy (Vinogradova et al., 2019).
• Testosterone therapy in physiologic ranges in women lacks evidence of increasing stroke risk; the largest safety concerns are dose-dependent, androgenic side effects.

Clinical reasoning:

• In patients with TIA history, I avoid high-dose oral estrogens; if menopausal therapy is needed, I consider transdermal estradiol at the lowest effective dose with aggressive vascular risk modification.
• For migraine, stabilizing sleep, reducing triggers, and improving cervical mechanics can decrease attack frequency; if hormones are used, we match route and dose to the vascular risk profile.

Integrative chiropractic fit:

• Cervicogenic contributions to migraine are significant. I employ gentle cervical mobilization, deep neck flexor training, scapular stabilization, and breathing strategies, which reduce trigeminocervical convergence and sympathetic reactivity.

References:

• Migraine, hormones, and stroke risk (Sacco et al., 2017)
• VTE/stroke risk by estrogen route in HRT (Vinogradova et al., 2019)

Estriol, Estradiol, Receptor Biology, and Skin

Estriol (E3) is a weaker estrogen with greater preference for ER-β; estradiol (E2) is potent and engages both ER-α and ER-β. For skin benefits:

• Estradiol improves collagen content, skin thickness, and elasticity more robustly than estriol because of its higher receptor potency (Callens et al., 2014).
• Estriol creams may provide relief of local skin or vulvovaginal symptoms with minimal systemic absorption, but are often insufficient for vasomotor symptoms.

Clinical reasoning:

• If vasomotor symptoms persist on estriol, I evaluate serum estradiol levels and consider adding or switching to low-dose transdermal estradiol, ensuring endometrial protection when needed.
• I avoid overreliance on “weak” estrogens for systemic symptoms; match the molecule to the therapeutic goal.

Integrative chiropractic fit:

• Collagen support is multifactorial; I combine adequate protein intake, resistance training, and photobiomodulation with careful spinal and fascial work to enhance tissue quality.

References:

• Skin and estrogens (Callens et al., 2014)

Thyroid Physiology, Reverse T3, and Getting the Dosing Right

I often see patients on levothyroxine (T4) who still feel unwell despite “normal” labs. Here is my framework:

• Physiology:

  • T4 monotherapy relies on peripheral conversion to T3; inflammation, caloric restriction, and stress can increase deiodinase 3 activity, raising reverse T3 (rT3) and reducing T3 signaling (Bianco et al., 2019).
  • Large, single daily T4 doses may transiently increase rT3 in sensitive individuals; desiccated thyroid or divided dosing of T3/T4 can improve some patients’ symptoms when carefully monitored.

• Testing:

  • TSH, free T4, free T3, reverse T3, thyroid peroxidase (TPO) antibodies, thyroglobulin antibodies, and ferritin/iron if symptoms persist.

• Clinical approach:

  • If free T3 is low-normal and symptoms remain, I consider adding small, divided doses of liothyronine (T3) or transitioning to combination therapy, while tracking heart rate, symptoms, and labs.
  • For Hashimoto’s, I pair thyroid hormone with gut-directed care (gluten assessment when appropriate, SIBO evaluation, selenium and vitamin D repletion, and iodine only when indicated).

Integrative chiropractic fit:

• Cervical and thoracic mobility improves breathing efficiency and sleep quality, which in turn modulates HPT-axis signaling. I also focus on anti-inflammatory nutrition and graded exercise to reduce rT3-driving stressors.

References:

• Thyroid hormone therapy: what’s new (Bianco et al., 2019)

Putting It Together: A Whole-Person Care Plan

I integrate endocrine pharmacology, precision diagnostics, and musculoskeletal-neuroautonomic care to amplify results:

• For iron deficiency with inflammation:
  • Treat the inflammatory trigger, appropriately replete iron, train breathing and sleep, and progress resistance exercise to improve erythropoiesis.
• For progesterone intolerance:
  • Switch to sublingual, adjust dose/timing, align with sleep hygiene, and leverage relaxation-based spinal care to reduce anxiety and improve tolerance.
• For male fertility on/off testosterone:
  • Time-limited clomiphene with lifestyle upgrades; add pelvic and thoracic mechanics to facilitate training and sleep.
• For complex breast histories:
  • Co-manage with oncology, use the safest route/dose possible when indicated, and maximize non-hormonal strategies for bone, brain, and vasomotor health.
• For thyroid symptom discordance:
  • Expand testing, consider combination therapy, and aggressively manage gut and sleep contributors while optimizing movement.

Clinical notes from my practice:

• In Sciatica Clinic cases, autonomic recalibration through diaphragmatic breathing combined with cervical-thoracic mobilization often reduces hot flashes and sleep fragmentation within 2–4 weeks.
• LinkedIn case threads highlight that structured resistance training 3 days/week, plus 30 minutes of zone 2 cardio 2 days/week, reliably improves insulin sensitivity and raises endogenous testosterone in young men without medications over 12–24 weeks.

Final Thoughts

Evidence-based hormone care is not about a single lab or a single drug. It is about understanding physiology—iron flux under hepcidin control; progestin family pharmacology; HPA and HPT axis rhythms; estrogen receptor biology—and then placing each therapy into a context that includes sleep, nutrition, biomechanics, and stress regulation. Integrative chiropractic care fits naturally within this model by improving pain, function, and autonomic balance, thereby enhancing adherence and magnifying the benefits of endocrine therapies. When we do this thoughtfully—guided by the latest research and careful shared decision-making—we help patients feel and function better, safely and sustainably.

References

• Hepcidin and iron homeostasis: from pathophysiology to clinical practice. Ganz, T., & Nemeth, E. (2012). Nature Reviews Immunology, 12(8), 503–510.
• Iron-deficiency anemia. Camaschella, C. (2015). New England Journal of Medicine, 372, 1832–1843.
• The levonorgestrel intrauterine system: mechanisms and clinical use. Nelson, A. (2021). Contraception, 104(2), 111–118.
• Progestogens and venous thromboembolism risk in hormone therapy. Canonico, M., et al. (2007). Circulation, 115(7), 840–845.
• Anesthetic and contraceptive considerations of progestins and thrombotic risk. Dragoman, M., et al. (2018). Anesthesia & Analgesia, 127(1), 116–123.
• Progesterone, neurosteroids, and affective regulation. Schiller, C. E., et al. (2014). Frontiers in Neuroendocrinology, 35(2), 315–328.
• HRT and breast cancer risk by progestogen type. Fournier, A., et al. (2008). American Journal of Epidemiology, 167(10), 1207–1215.
• Diurnal cortisol rhythms and health outcomes. Adam, E. K., et al. (2017). Psychoneuroendocrinology, 83, 25–41.
• Clomiphene citrate for male hypogonadism and fertility. Patel, A. S., et al. (2019). Andrology, 7(4), 530–537.
• Management and outcomes of DCIS. Wapnir, I. L., & Dignam, J. J. (2019). Journal of Clinical Oncology, 37(26), 2201–2203.
• The 2023 nonhormone and hormone therapy position statements. North American Menopause Society (2023).
• Migraine, estrogen, and stroke risk: a review. Sacco, S., et al. (2017). Stroke, 48(7), 1996–2003.
• Use of HRT and risk of VTE and ischemic stroke by route. Vinogradova, Y., et al. (2019). BMJ, 364, k4810.
• Estrogens and skin physiology. Callens, A., et al. (2014). Archives of Dermatological Research, 306(7), 595–606.
• Treatment of hypothyroidism: current approaches. Bianco, A. C., et al. (2019). New England Journal of Medicine, 381, 749–761.